Anthracyclines News and Research

RSS

Remote ischemic conditioning shields the heart from chemotherapy damage

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective anticancer drugs-a class of medicines called anthracyclines-can cause serious damage to the heart.

2 Mar 2026

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

New chemotherapeutic agent shows remarkable efficacy against multiple tumor types

A research team led by the Medical University of Vienna, the HUN-REN Research Centre for Natural Sciences and the Eötvös Loránd University in Budapest has developed a groundbreaking new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor types in preclinical studies.

30 Oct 2025

ESC and EAS release new dyslipidaemia guidelines

The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) have just published the new international recommendations for managing dyslipidaemias. They were presented at the Annual Cardiology Congress held in Madrid from August 29th to September 1st, 2025.

2 Sep 2025

New genomic test predicts chemotherapy resistance in cancer patients

Chemotherapy seeks to destroy tumor cells and has been a standard treatment for cancer for decades.

24 Jun 2025

New clinical trial tests non-invasive method to protect hearts during chemotherapy

A simple intervention, similar to the tension applied to the arm during a blood pressure reading, is being tested in a Phase II clinical trial to see if it can help cancer patients treated with common chemotherapy drugs, called anthracyclines, avoid heart failure.

20 Jun 2025

Breast cancer survivors face accelerated aging tied to tumors and treatment

Accelerated aging in breast cancer survivors is linked to treatments and tumor characteristics, with implications for long-term care and quality of life.

20 Mar 2025

Scientists design strategy for preventing cardiotoxic effects of anthracyclines

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic effects of anthracyclines, a widely used class of anticancer drugs.

4 Feb 2025

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

FarrSight-Twin technology transforms cancer treatment research

Researchers have shown that they can accurately re-create clinical trials of new treatments using 'digital twins' of real cancer patients.

24 Oct 2024

Multigene RNA signature enhances treatment strategies for triple negative breast cancer

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise as a way to improve disease-free survival, finds a clinical trial published by The BMJ today.

23 Oct 2024

NYU Langone researchers address the challenges of heart failure in cancer patients

A new scientific statement issued today by the Heart Failure Society of America highlights a critical connection between heart failure (HF) and cancer, with shared mechanisms contributing to the incidence and progression of both diseases.

16 Oct 2024

SwRI collaborates with UTSA to develop novel chemical process for synthesizing antibiotics

Southwest Research Institute (SwRI) is collaborating with The University of Texas at San Antonio (UTSA) to explore and develop a novel platform or chemical process for synthesizing antibiotic compounds with a $125,000 grant.

17 Sep 2024

ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage

Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with heart damage, at one month after their last chemotherapy dose compared with those who did not take an ACE inhibitor, according to a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Childhood cancer treatment linked to higher breast cancer risk

Women who have been treated for cancer as a child with a certain type of chemotherapy have an increased risk of breast cancer, according to a large-scale international study of survivors of childhood cancer led by scientists from the Princess Máxima Center for pediatric oncology.

11 Sep 2023

Anthracyclines News and Research

Remote ischemic conditioning shields the heart from chemotherapy damage

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

New chemotherapeutic agent shows remarkable efficacy against multiple tumor types

ESC and EAS release new dyslipidaemia guidelines

New genomic test predicts chemotherapy resistance in cancer patients

New clinical trial tests non-invasive method to protect hearts during chemotherapy

Breast cancer survivors face accelerated aging tied to tumors and treatment

Scientists design strategy for preventing cardiotoxic effects of anthracyclines

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

FarrSight-Twin technology transforms cancer treatment research

Multigene RNA signature enhances treatment strategies for triple negative breast cancer

NYU Langone researchers address the challenges of heart failure in cancer patients

SwRI collaborates with UTSA to develop novel chemical process for synthesizing antibiotics

ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage

Childhood cancer treatment linked to higher breast cancer risk

ER-phagy alleviates drug-induced cardiomyopathy in cancer patients

Five-year survival of children with acute lymphatic leukemia continues to increase

Young adult cancer survivors at higher risk of heart failure when treated with anthracyclines

Study highlights the interconnectedness of autoimmunity and cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News